zavegepant (Zavzpret)
Jump to navigation
Jump to search
Indications
Dosage
Pharmacokinetics
- rapid onset of action ~15 minutes
Mechanism of action
More general terms
References
- ↑ Lipton RB, Croop R, Stock DA et al Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo- controlled multicentre trial. Lancet Neurol. 2023 Mar;22(3):209-217. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36804093
- ↑ HIGHLIGHTS OF PRESCRIBING INFORMATION ZAVZPRET <TM> (zavegepant) nasal spray https://labeling.pfizer.com/ShowLabeling.aspx